CLAY THORP

Clay Thorp stands as a distinguished General Partner and co-founder of Hatteras Venture Partners, a leading venture capital firm dedicated to advancing innovation in the life sciences sector. As a cornerstone of Hatteras, Mr. Thorp has been instrumental in shaping the firm's investment strategy and fostering a portfolio of groundbreaking companies that address critical healthcare needs. His leadership at Hatteras Venture Partners underscores a deep commitment to identifying and nurturing early-stage ventures with the potential for transformative impact.

Mr. Thorp's investment focus at Hatteras Venture Partners spans a broad spectrum of the life sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health. He is particularly adept at recognizing companies poised to develop novel therapeutics, cutting-edge medical technologies, and innovative healthcare solutions. His approach is characterized by a hands-on engagement with portfolio companies, often serving on their boards, providing strategic guidance, and leveraging his extensive network to support their growth from scientific concept to market realization.

Before co-founding Hatteras Venture Partners, Clay Thorp built a formidable career marked by significant entrepreneurial success. He co-founded and served in leadership roles for several pioneering life science companies, including Novalon Pharmaceutical Corporation, which was later acquired by a major pharmaceutical firm. This direct experience as an entrepreneur provides him with invaluable insights into the challenges and opportunities faced by early-stage companies, making him a highly empathetic and effective investor. His background equips him to understand the scientific rigor, operational complexities, and market dynamics essential for success in the life sciences.

Throughout his tenure, Clay Thorp has been a driving force behind numerous successful investments that have brought important medical advancements to patients. While specific investment details often remain confidential, his portfolio includes companies that have achieved significant milestones, such as successful clinical trials, regulatory approvals, and lucrative exits through acquisitions or initial public offerings. For instance, his involvement with companies like G1 Therapeutics, which went public and developed innovative cancer therapies, exemplifies his ability to back ventures that make a tangible difference in patient care. His strategic vision helps guide these companies through critical development phases, ultimately contributing to the broader healthcare ecosystem.

Clay Thorp's profound expertise, coupled with his entrepreneurial spirit and dedication to scientific innovation, positions him as a pivotal figure in the venture capital landscape. He continues to seek out visionary founders and disruptive technologies, reinforcing Hatteras Venture Partners' reputation as a premier investor in the dynamic and vital field of life sciences.